bioAffinity Technologies, Inc. announced on July 15, 2025, that it received notification of allowance from the China National Intellectual Property Administration (CNIPA) for a patent application. The patent relates to methods of predicting the likelihood of lung cancer using flow cytometry, the core technology of CyPath® Lung.
The newly allowed Chinese patent, titled 'System and Method for Determining Lung Health,' protects the use of defined antibodies and the porphyrin TCPP to label cell populations in sputum for lung cancer detection. This strengthens the international protection of the company's diagnostic platform.
China represents a substantial prospective market for CyPath® Lung, with over 300 million smokers and an estimated 1.06 million new lung cancer cases diagnosed in 2022. Securing this intellectual property positions bioAffinity Technologies for future opportunities in a market with a high burden of lung cancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.